Finney Elisha W, director at Icu Medical, sells $180k in shares

ICU Medical Inc. (ICUI) significantly surpassed third-quarter 2025 earnings expectations, reporting an adjusted EPS of $2.03 and revenue of $537 million, prompting management to raise full-year guidance. Following these strong results, Piper Sandler increased its price target to $172 with an Overweight rating, contributing to a 12.44% surge in the stock over the past week. While a director recently sold shares after exercising options, the company maintains a "GOOD" financial health score and analysts anticipate net income growth this year, despite unprofitability over the last twelve months, with InvestingPro suggesting the stock is slightly undervalued.

Analysis

ICU Medical Inc. (ICUI) reported a robust third-quarter 2025, significantly surpassing analyst expectations with an adjusted EPS of $2.03 against a forecast of $1.42, representing a 42.96% surprise. Revenue also exceeded projections, reaching $537 million compared to the anticipated $510.44 million, driven by strong segment performance and notable margin outperformance. This strong financial performance prompted management to raise full-year guidance for both EBITDA and adjusted EPS.

Following these positive developments, ICUI's stock surged 12.44% over the past week, currently trading at $139.93. Piper Sandler responded by increasing its price target from $153 to $172 while maintaining an Overweight rating, reflecting increased confidence in the company's outlook. Needham, however, maintained a Hold rating on the stock despite the impressive quarterly results.

InvestingPro data indicates ICUI maintains a "GOOD" financial health score, with analysts expecting net income growth this year, despite the company not being profitable over the last twelve months. The stock also appears slightly undervalued based on Fair Value estimates. A director recently exercised options to acquire 1,285 shares at $103.76 and subsequently sold the same number of shares at $140.42, capitalizing on the recent stock appreciation.

Key Decisions for Investors

• Investors should closely monitor ICUI's execution on its raised full-year guidance and the trajectory of net income growth, given its recent unprofitability.
• Evaluate the stock's current valuation relative to Piper Sandler's increased price target of $172 and InvestingPro's "slightly undervalued" assessment.
• While a director sold shares, consider this as profit-taking following a significant stock surge rather than a fundamental negative signal, especially after exercising options.